AstraZeneca, Daiichi Sankyo claim PhIII lung cancer win for ADC — but shares fall

AstraZeneca and Daiichi Sankyo’s multibillion-dollar antibody-drug conjugate alliance has generated a Phase III win, the partners say, beefing up the case that they have a broadly applicable lung cancer drug in the pipeline.

But a vague mention of patient deaths and the absence of more enthusiastic language is spurring questions…
Click here to view original post

Advertisement — Advertise with Biotech Networks